Target the Cause.
Stop the Cysts.
Turning biological insights into life-changing therapies.
At xCystence Bio, we are developing a new therapeutic strategy for polycystic kidney disease. Using targeted protein degradation (TPD), we aim to selectively eliminate the protein driving cyst formation, rather than inhibiting its kinase activity.
Our lead programme uses TPD to deplete AURKA, which Monash research identified as a master regulator of renal cyst development (Nature Communications, 2024).
Investors
